Diane Heiser Joins Synthyra as Advisor

NEWARK, DE, August 10, 2026. Synthyra Public Benefit LLC today announced that Diane Heiser, PhD, has joined the company as an advisor. She will advise the team on company building, scientific translation, and partnerships as Synthyra grows its commercial research products and advances systems-guided biological design programs.

Heiser is a biotech executive and scientific founder who has built research teams, scaled technology platforms, and advanced precision-medicine programs. Her work with Synthyra will focus on turning scientific capability into clear programs, partner opportunities, and product decisions.

“Diane brings the operating perspective Synthyra needs at this stage: how to turn deep scientific capability into a company model that customers, partners, and investors can understand,” said Braydon McCormick, PhD, CEO of Synthyra. “Her feedback has already sharpened how we connect our technical depth to decisions in translational research, biotech partnerships, and drug discovery.”

Synthyra's commercial research products predict protein-protein interaction, protein-ligand interaction, and functional annotation at proteome scale. Those predictions feed a broader objective: therapeutic, enzyme, and metabolic programs chosen for the disease response and toxicity they produce at the systems level, not for a single molecular property such as an interface score.

“The most valuable scientific platforms do more than generate interesting predictions; they help teams make better decisions,” said Diane Heiser. “Synthyra is compelling because it designs for the outcome a program has to produce at the systems level, not for one property of a molecule along the way. That is the translational question researchers and companies actually need answered.”

Synthyra is opening limited product access for research teams and speaking with experimental, therapeutic-development, and strategic partners.

About Diane Heiser

Diane Heiser, PhD, is a biotech executive and scientific founder. She co-founded Notable Labs, where she helped build a high-throughput personalized-medicine platform for blood cancer research and led its scientific and technology work. She has held translational research leadership roles in oncology and precision medicine, and she advises early-stage biotech companies.

About Synthyra

Synthyra is a systems-guided biological design company. It optimizes the outcome of a biological design campaign at the systems level, not a single property of the underlying molecules. Its commercial research products model protein-protein interaction, protein-ligand interaction, and functional annotation at proteome scale, and its internal programs apply that context to select therapeutic, enzyme, and metabolic candidates on predicted disease response and toxicity rather than on a single property alone, such as an interface metric.

Media Contact

Media team: [email protected] www.synthyra.com